GLP-1 Medicaid Coverage by State: 2026 Tracker

By The RX Index Editorial Team · The RX Index Research, an independent research and reference resource on prescription-drug access and coverage

GLP-1 Medicaid coverage by state changes fast, and it has been shrinking. As of July 2, 2026, we verified 11 state Medicaid programs that cover GLP-1 drugs for weight loss — down from the 13 that KFF counted in January 2026, after Massachusetts ended its coverage on July 1. A 12th state, Utah, is unresolved: its coverage was a legislative pilot scheduled to expire June 30, 2026, and we could not confirm whether it was renewed. Every other state still covers these same drugs for type 2 diabetes, cardiovascular risk, sleep apnea, or other approved conditions — just not for weight loss by itself.

That is the whole tension of this topic in three sentences. The drug your neighbor gets covered for weight loss in one state is excluded one state over, because a single line in federal law lets each state decide. Below is the full picture — which states cover it, what they actually cover, what changed in 2026, and what your options are if your state is not on the list. No sign-ups, no forms, nothing to sell. Just the data and the sources behind it.

GLP-1 Medicaid coverage by state: the bottom line

GLP-1 weight-loss coverage under Medicaid usually means Wegovy, Zepbound, or Saxenda covered for obesity — almost always with prior authorization (a doctor has to get the drug approved before the pharmacy can fill it). It is not the same as coverage for Ozempic or Mounjaro for diabetes, which every state provides. The states below are the ones where an FDA-approved anti-obesity GLP-1 is covered for weight loss without requiring a separate qualifying diagnosis, as of our July 2, 2026 check.

Source: The RX Index Research, compiled July 2, 2026 from state Medicaid Preferred Drug Lists, prior authorization forms, and provider bulletins, cross-checked against KFF (Jan 2026) and Stateline reporting (Apr 2026). Coverage reflects fee-for-service policy and typically requires prior authorization; a state’s managed-care plans and the current PDL version may differ. Confirm current status with your state Medicaid agency before relying on it.

What this data shows — and what it doesn’t

This tracker answers one question: does a state’s Medicaid program cover GLP-1 drugs for weight loss — meaning obesity or chronic weight management — without requiring a separate diagnosis like diabetes? That is it. It does not measure how many people actually get approved, and it does not guarantee any individual will be covered. Approval still depends on prior authorization, BMI thresholds, step therapy, and a prescriber’s documentation.

Three things it deliberately keeps separate. First, weight-loss coverage is not diabetes coverage; a state can cover Ozempic for diabetes and exclude Wegovy for weight loss, and most do. Second, fee-for-service Medicaid (run directly by the state) can differ in the fine print from a Medicaid managed-care plan (run by a private insurer under contract). Third, a drug appearing on a state’s drug list is not proof it is covered for weight loss specifically — which is exactly the mist this page is designed to clear.

How we built this tracker

We started from the most authoritative count available and updated it from primary sources. KFF, the health-policy research organization, publishes the recognized national count of state Medicaid GLP-1 coverage for obesity. We took KFF’s January 2026 figure of 13 states, identified the specific states from KFF’s data as reported by Stateline, and read the primary state documents for each.

Our process, in order:

1. Anchored to KFF’s January 2026 count of 13 state fee-for-service programs covering GLP-1s for obesity.
2. Identified the specific states from KFF’s data as reported by Stateline, cross-checked against Milliman.
3. Read the primary state documents — provider bulletins, Preferred Drug Lists, and prior authorization forms — for the covering states, the recently-changed states, and the high-restriction states.
4. Classified a state as “covers for weight loss” only when its own source supports coverage for obesity or weight management, not diabetes or another indication.
5. Recorded the source and a verification date for each entry, and flagged what we could not confirm at the source — chiefly Utah’s pilot renewal.

We use first-person plainly here because it matters for trust: where we say “we read the source,” we mean we opened the state’s own document, not a summary of it. Where we could not, we say so.

Two honest limitations up front. We did not independently re-open all 50 state drug lists in this pass. For the covering roster we relied on KFF’s and Stateline’s naming plus the state sources we could reach; for the states not listed, we rely on KFF’s count rather than 38 separate drug-list reads. And drug-level detail — which exact product a state prefers — changes often, so treat each row’s source as a pointer to the live document, not a permanent snapshot.

Which states cover GLP-1 medications for weight loss through Medicaid?

As of July 2, 2026, the states with verified Medicaid coverage for GLP-1 weight-loss drugs are Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Virginia, and Wisconsin. Utah’s coverage is unresolved after a pilot scheduled to expire June 30, 2026. Coverage almost always requires prior authorization, and several of these states limit it with BMI thresholds, step therapy, or age rules.

Everywhere else, Medicaid covers GLP-1s only for a medically approved condition other than weight loss, typically with prior authorization. That is the practical takeaway for most enrollees: if your state is not in Table 1, your Medicaid program covers these drugs for diabetes, cardiovascular risk, sleep apnea, or MASH — but not for weight loss by itself.

A few states deserve a closer note. Michigan cut its coverage on January 1, 2026, to only those with a BMI of 40 or higher who have failed other options and are trying to avoid bariatric surgery — one of the strictest policies in the country. The University of Michigan Medical School, whose faculty helped inform the state’s original coverage decision, describes the new rule as covering only beneficiaries with a BMI of 40 or greater, defined as morbid obesity. North Carolina removed coverage in October 2025 for budget reasons, then reinstated it on December 12, 2025 — a reminder that these decisions can reverse on short notice. Rhode Island currently covers the drugs, but its governor proposed removing them in the FY2027 budget; that proposal was not enacted as of publication, so Rhode Island remains in the table. Massachusetts, which KFF counted among its 13 as of January 2026, ended weight-loss coverage on July 1, 2026, dropping the verified total to 11.

Diabetes vs. weight loss: why the same drug is covered for one and not the other

The same molecule can be covered or denied depending on the diagnosis on the prescription. Federal law requires Medicaid to cover a drug’s FDA-approved “medically accepted indications,” but it carves out weight loss as something states may exclude. So semaglutide is covered nationwide when it’s Ozempic for diabetes, yet covered for obesity (as Wegovy) in only 11 verified states.

This is the distinction that trips people up, and it is worth getting exactly right. GLP-1 drugs were first approved for type 2 diabetes and later for weight management and other conditions. The FDA approves specific brand-and-indication pairings, and Medicaid coverage follows the indication, not just the drug. Coverage for the non-weight-loss indications is required in every state; coverage for weight loss is optional.

Source: The RX Index Research; indication status per FDA approvals and the federal Medicaid drug statute (42 U.S.C. § 1396r-8). “Required” coverage is still subject to each state’s prior authorization and medical-necessity rules. Last verified July 2, 2026.

The practical upshot: if you have one of the required conditions, there is a coverage pathway in every state — though approval still depends on prior authorization and medical-necessity criteria. If your only reason is weight loss, that pathway exists in 11 states. This is also why “does Medicaid cover Wegovy?” has no single answer: Wegovy is covered everywhere for cardiovascular risk and MASH, but for weight loss only in the covering states.

There is one more protection worth knowing. EPSDT — Early and Periodic Screening, Diagnostic, and Treatment — is a federal Medicaid requirement to cover medically necessary care for anyone under 21, even treatments that are excluded for adults. That means a blanket “we don’t cover weight-loss drugs” rule cannot automatically be applied to a 17-year-old. When Pennsylvania ended adult obesity coverage in January 2026, it explicitly kept the under-21 pathway open for this reason.

Why Medicaid GLP-1 coverage varies so much by state

Coverage varies because a single provision of federal Medicaid law lets states exclude drugs used for weight loss. The statute lists a handful of drug categories states are allowed to leave out, and among them are agents used for weight loss. Diabetes drugs are not on that list, so their coverage is effectively mandatory; weight-loss drugs are, so their coverage is a choice.

You can read the exclusion yourself in the U.S. Code. It dates back long before GLP-1s existed, written in an era when “weight-loss drugs” meant something very different. But it is the reason a person on Medicaid in one state gets Wegovy for obesity and a person one state over does not.

The rest is budget math. GLP-1s are expensive, demand is enormous, and states absorb the cost of an optional benefit. According to KFF, almost 40% of adults and about a quarter of children covered by Medicaid have obesity — a very large potential population. When a state adds obesity coverage, spending climbs fast; when budgets tighten, the optional benefit is first on the table. That dynamic is what is driving the 2026 pullback.

Which states stopped covering Medicaid GLP-1s for weight loss in 2026?

After peaking at 16 states in October 2025, Medicaid coverage of GLP-1s for weight loss has contracted, and the direction of travel is clearly down. Four states ended coverage on January 1, 2026, Michigan sharply restricted it the same day, and Massachusetts ended it July 1, 2026. The only recent additions — Missouri, Tennessee, and Utah — came earlier, and Utah’s was a time-limited pilot.

Here is every change we verified, with dates, direction, and sources.

Source: The RX Index Research, from state Medicaid bulletins and KFF. Last updated July 2, 2026.

The arc of the count is itself the story, and it is a clean thing to cite.

Source: KFF (Aug 2024, Oct 2025, Jan 2026) and The RX Index Research (Jul 2026). Last verified July 2, 2026.

The common thread among the states that ended coverage was cost, though the sources do not all say it the same way. KFF attributes the pullback largely to recent state budget challenges and the significant cost of coverage. Several states put it more bluntly: California’s spending on the three weight-loss GLP-1s roughly quadrupled between early 2024 and mid-2025, per Milliman’s analysis; New Hampshire called the drugs a “significant cost driver”; and Massachusetts estimated it would save about $15 million a year, with its Medicaid director calling the drugs’ prices “unsustainable” while adding that the state hopes to offer them again if prices fall. Rhode Island’s governor has proposed removing coverage too, though as of this writing it had not been enacted — which is why Rhode Island still appears in Table 1.

Does Medicaid cover Wegovy, Zepbound, Ozempic, or Saxenda?

It depends on the drug and the reason it is prescribed. Ozempic and Mounjaro are diabetes drugs; Medicaid covers them nationwide for diabetes but not for weight loss, because they are not FDA-approved for obesity. Wegovy, Zepbound, and Saxenda are the weight-loss drugs, and those are covered for obesity only in the states in Table 1 — though Wegovy and Zepbound are also covered everywhere for their non-weight-loss uses.

• Ozempic (semaglutide): A diabetes drug. Covered nationwide for type 2 diabetes, generally with prior authorization. Not covered for weight loss because it is not FDA-approved for that use.
• Wegovy (semaglutide): Covered nationwide for cardiovascular risk reduction and for noncirrhotic MASH. Covered for weight loss only in the covering states.
• Zepbound (tirzepatide): Covered nationwide for moderate-to-severe obstructive sleep apnea in adults with obesity. Covered for weight loss only in the covering states.
• Mounjaro (tirzepatide): A diabetes drug. Covered nationwide for type 2 diabetes, generally with prior authorization.
• Saxenda (liraglutide): An older weight-loss drug. Where covered, it is often a required first step before newer agents; some states cover it for adolescents under EPSDT.

Where states differ on the newer drugs, we saw it directly in the sources. North Carolina covers Wegovy and Zepbound for obesity but removed Saxenda when it reinstated coverage. Missouri lists Zepbound as preferred and Wegovy as non-preferred on its obesity GLP-1 drug list. Michigan covers Saxenda, Wegovy, and Zepbound for obesity but only at a BMI of 40 or higher. If you are in a covering state, expect prior authorization and, usually, a BMI requirement — commonly a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure.

What to do if your state’s Medicaid doesn’t cover GLP-1s for weight loss

“Not covered for weight loss” is not the same as “no path at all.” Every state covers these drugs for several medical conditions, members under 21 have separate federal protection, and a new federal program may expand access. None of this is a workaround — it is the set of legitimate coverage routes that already exist.

Source: The RX Index Research; KFF; CMS; Medi-Cal Rx; Pennsylvania DHS. Last verified July 2, 2026.

A few plain-language notes on using these. If you have type 2 diabetes, established cardiovascular disease, moderate-to-severe sleep apnea, or noncirrhotic MASH, a GLP-1 may be covered on that basis in any state — talk to your prescriber about whether one genuinely applies. Where coverage exists it almost always requires prior authorization, and a denial is not necessarily the end: you can request the specific clinical criteria and the reason in writing and appeal through your state’s fair-hearing process. Sometimes a denial is just a missing BMI or comorbidity note. And your state Medicaid agency and Medicaid.gov are the authoritative places to confirm what is covered for you right now.

This is educational information, not medical or legal advice. Coverage decisions are made by your state, your plan, and your prescriber.

Will the federal BALANCE Model change Medicaid GLP-1 coverage?

Maybe, for Medicaid — but not for Medicare in 2027, and not as a guarantee for anyone. This is the part of the 2026 story that is easiest to get wrong, so here is the current, sourced version. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a voluntary CMS demonstration that negotiates lower GLP-1 prices directly with manufacturers. The Medicaid piece is moving forward; the Medicare Part D piece was delayed indefinitely in April 2026, and a separate short-term program, the Medicare GLP-1 Bridge, now carries Medicare through 2027.

Source: The RX Index Research, from the CMS BALANCE Model and Medicare GLP-1 Bridge pages and KFF. Last verified July 2, 2026.

Two details worth pinning down because Medicare readers will confuse the Bridge with Medicaid. The Bridge covers a specific, limited set of products: per CMS, the eligible drugs are Foundayo, Wegovy (injection and tablets), and the Zepbound KwikPen — the single-dose Zepbound pen and vials are not included. And it only covers GLP-1s used for weight loss; Medicare enrollees who use them for diabetes, sleep apnea, or MASH stay on their regular Part D plan. For a person on Medicaid today, BALANCE is a “watch this space,” not a coverage guarantee — whether it helps you depends on your state’s decision. For a full explainer on the Medicare GLP-1 Bridge, see the Medicare GLP-1 Bridge Tracker.

GLP-1 Medicaid coverage statistics: spending, prescriptions, and the data’s limits

GLP-1s are a small slice of Medicaid prescriptions but a fast-growing chunk of drug spending, and that growth is the whole reason states are cutting the optional benefit.

Source: KFF analysis of CMS Medicaid drug data. Figures are gross of manufacturer rebates, so the net cost to states is lower. Last verified July 2, 2026.

Two caveats make these numbers citable rather than misleading. The spending figure is gross, meaning it does not reflect the substantial rebates manufacturers pay states, so the net cost is lower. And the public data cannot separate how much of that use was for diabetes versus obesity versus the other approved conditions — KFF says so explicitly. What is clear is the trajectory: utilization and spending are up sharply, and that pressure is what is pushing states to treat obesity coverage as the optional benefit the law says it is.

Why this matters now

Medicaid GLP-1 coverage for weight loss is moving faster than almost any other benefit, and it is moving in one direction. In roughly a year, the count went from 13 states to 16 and back to 13, and then to 11 verified — with more cuts proposed. For the nearly four in ten adult Medicaid enrollees with obesity, whether an effective treatment is covered can now depend on the state line and the calendar. That is the reality this tracker exists to document accurately, on a specific date, from the sources that decide it.

Limitations

We would rather you trust this page because we are clear about its edges than because we oversold it.

• Coverage changes often, sometimes off-cycle. State pharmacy policies frequently change on January 1 and July 1, and sometimes mid-year. This is a snapshot dated July 2, 2026.
• Fee-for-service versus managed care. Our classification reflects state fee-for-service policy. A specific Medicaid managed-care plan may apply different details.
• A drug on a list is not proof of weight-loss coverage. A GLP-1 can appear on a state’s drug list for diabetes while being excluded for weight loss. We classified by indication, but always confirm with the state.
• Utah is unresolved. Utah’s weight-loss coverage was a pilot scheduled to end June 30, 2026; we could not confirm a renewal, so we report 11 verified states and treat Utah as pending.
• We relied on KFF’s count for the non-covering states. We did not independently re-read all 50 drug lists in this pass; states not listed in Table 1 are treated as non-covering based on KFF’s January 2026 count.
• Spending data cannot split GLP-1 use by indication, and is gross of rebates.

Frequently asked questions

How to cite this page

Primary sources

• KFF "Medicaid Coverage of and Spending on GLP-1s" (Jan 16, 2026).
• KFF "What to Know About the BALANCE Model and the Medicare GLP-1 Bridge" (updated May 11, 2026).
• U.S. Code 42 U.S.C. § 1396r-8 (Medicaid drug coverage and the weight-loss exclusion).
• CMS BALANCE Model.
• CMS Medicare GLP-1 Bridge — Information for Part D Plans.
• Medi-Cal Rx (California) GLP-1 coverage change notice.
• Pennsylvania DHS Medical Assistance Bulletin.
• NC Medicaid Reinstatement notice, Dec 19, 2025.
• Michigan MDHHS Letter L-25-73.
• University of Michigan Medical School Expert Q&A on Michigan’s GLP-1 limits.
• Utah Medicaid GLP-1 weight-loss prior authorization form.
• Massachusetts (Mass.gov) June update on GLP-1 coverage.
• Milliman "The evolving landscape of anti-obesity medication coverage in Medicaid" (Mar 2026).
• Stateline "More states consider dropping GLP-1 weight loss drugs from Medicaid" (Apr 30, 2026).

Benchmark figures are refreshed as KFF and state sources update; named-state rows are re-checked monthly and during policy cycles. Report date of last full verification: July 2, 2026.